Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00919750 Completed - Ependymoma Clinical Trials

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Start date: February 16, 2004
Phase:
Study type: Observational

The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.

NCT ID: NCT00918320 Completed - Solid Tumors Clinical Trials

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours

TOTEM2
Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.

NCT ID: NCT00915863 Recruiting - Clinical trials for Pancreatic Neoplasms

Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy

Start date: June 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the incidence of complications with the isolated Roux-en-Y reconstruction after pancreaticoduodenectomy in pancreatic tumor and periampullary tumor patients. A prospective randomized controlled trial was conducted to compare the incidence of complications with isolated Roux-en-Y reconstruction with those of Billroth-II-type reconstruction after pancreaticoduodenectomy.

NCT ID: NCT00915083 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

Start date: June 1, 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors. The study will assess the pharmacokinetics of the amrubicin and if it has an effect on the heart.

NCT ID: NCT00909402 Completed - Stomach Neoplasms Clinical Trials

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric, gastroesophageal or esophageal adenocarcinomas.

NCT ID: NCT00908869 Completed - Advanced Neoplasm Clinical Trials

Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm

METRO1
Start date: May 2006
Phase: Phase 1
Study type: Interventional

Purpose: This phase I trial estimates the antiangiogenic and antivascular effect of 4 different levels of continuous low doses of the combination of Vinorelbine, Cyclophosphamide and Interferon alpha 2b (" metronomic chemotherapy ")in adult advanced neoplasm. This study is non randomized, monocentric, and with a pharmacodynamic part. Primary objective: Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b. Secondary objectives: Estimation of the antiangiogenic and/or antivascular effect (VEGF measurement) in radiography (DEC-MRI), biology and immunohistochemistry of the treatment.

NCT ID: NCT00907738 Completed - Advanced Cancer Clinical Trials

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

NCT ID: NCT00906698 Completed - Neoplasms Clinical Trials

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Start date: June 2009
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose, safety, pharmacokinetics and anti-tumour efficacy of oral BIBW 2992 in combination with intravenous or oral vinorelbine

NCT ID: NCT00904787 Completed - Clinical trials for Relapsed or Refractory Hematological Malignancies

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Start date: April 2009
Phase: Phase 1
Study type: Interventional

To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies

NCT ID: NCT00903708 Completed - Advanced Cancers Clinical Trials

LY2275796 in Advanced Cancer

Start date: September 2006
Phase: Phase 1
Study type: Interventional

Primary Objective: - To determine a recommended Phase 2 dose of LY2275796 that may be safely administered to patients with advanced cancer, with prospects for therapeutic biologic effects. This will require simultaneous: - monitoring of toxicities & determination of maximal tolerated dose (MTD) - detecting eIF-4E target inhibition in tumor - pharmacokinetic measurements Secondary Objectives: - To estimate pharmacokinetic parameters of LY2275796 and explore pharmacokinetic/pharmacodynamic relationships - To document any antitumor activity observed with LY2275796